Health Matters
  • Home
  • About
  • Our Services
  • News
    • Top Stories
    • Recent News
    • Archive
  • Subscribe
  • My Account
    • My profile
    • Corporate Account
    • Cancel
    • Orders
    • Billing
  • Contact
  • Login

Global Fund Replenishment: Addressing Critical Needs

by Eric Mthobeli Naki | The Citizen | 29 September 2025 | Sep 30, 2025 | Archive, September 2025

Learn why Global Fund replenishment is critical to combat AIDS, TB, and malaria amid severe health financing cuts.

Subscription Required

You must be a subscriber to access all of this content.

View Subscriptions

Already a subscriber? Log in here

Lenacapavir Access Under Scrutiny by Health Advocates

by Tara Roos | Business Day | 26 September 2025 | Sep 30, 2025 | Archive, September 2025

Explore the urgent call for lenacapavir access, as advocates seek equitable HIV prevention for all communities worldwide.

Subscription Required

You must be a subscriber to access all of this content.

View Subscriptions

Already a subscriber? Log in here

UNAIDS Closure Causes Outrage Among Health Advocates

by Luyolo Mkentane | Business Day | 26 November 2025 | Sep 30, 2025 | Archive, September 2025

Activists warn that the UNAIDS closure will critically affect HIV/AIDS progress, calling for urgent global health action.

Subscription Required

You must be a subscriber to access all of this content.

View Subscriptions

Already a subscriber? Log in here

Precision Medicine: Transforming Treatment Approaches

by Asgar Rangoonwala | The Citizen | 26 September 2025 | Sep 30, 2025 | Archive, September 2025

Discover the impact of precision medicine on mental health and oncology, offering hope through targeted therapies and treatments.

Subscription Required

You must be a subscriber to access all of this content.

View Subscriptions

Already a subscriber? Log in here

NHLS Cancer Testing Delays Outsourcing Solutions

by Tamar Kahn | Business Day | 25 September 2025 | Sep 29, 2025 | Archive, September 2025

Understanding NHLS cancer testing delays reveals a healthcare crisis. See how private sector labs are aiding in urgent testing.

Subscription Required

You must be a subscriber to access all of this content.

View Subscriptions

Already a subscriber? Log in here

Generic HIV Prevention Drug to Cost Just $40 Annually from 2027

by Rishika Sadam and Jennifer Rigby | Reuters | 24 September 2025 | Sep 29, 2025 | Archive, September 2025

Explore the benefits of the generic HIV prevention drug lenacapavir, set to change the landscape of global health by 2027.

Subscription Required

You must be a subscriber to access all of this content.

View Subscriptions

Already a subscriber? Log in here
« Older Entries
Next Entries »

Recent Posts

  • NHLS Scrambles as Pathology Services Funding Runs Dry
  • Momentum Group Posts Record Earnings
  • Sanlam Writes Down AfroCentric to Nil but Won’t Sell
  • GLP-1 Alone Won’t Solve South Africa’s Diabetes Crisis
  • Aspen Bets Recovery on Filling Sterile Manufacturing Lines

Recent Comments

No comments to show.
Health Matters

Independent healthcare news and analysis for professionals across Southern Africa. Published since 1994.

  • Follow
  • Follow
  • Follow

QUICK LINKS

Home

About

Our Services

Subscribe

Contact

Account

Top Stories

Recent News

Archive

Login

CONTACT



+27 (0)828963143



trevor@health-matters.io



29a Lourensford Rd, Cape Town, 7130

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}